Robert Dodd; Analyst; Raymond James & Associates, Inc. Good morning, and welcome to the PennantPark Floating Rate Capital's first fiscal quarter 2025 earnings conference call. Today's conference ...

LONDON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- A.P. Moller - Maersk (Maersk), one of the world’s largest containership operators, and Inmarsat Maritime, a Viasat company, have signed an agreement to ...

floating an abridged piece of legislation as the conference remains at odds over spending cuts. Throughout the budget reconciliation process, Republicans have been operating under the assumption ...

Trump will sign a transgender sports ban his afternoon. President Trump set off a fireball in Middle East tensions Tuesday by floating the idea of the U.S. taking control of the Gaza Strip ...

Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia, or SCA ...

Chinese state-owned manufacturing giant CRRC has installed a prototype 20MW floating offshore wind turbine that's among the largest ever erected globally. CRRC – best known as a leading railway ...

Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...

(MENAFN- PR Newswire) Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, "Our NDA filing is the culmination of over 8 years of clinical research and represents an ...

Check Out Our Latest Analysis on BHVN Biohaven Stock Performance Shares of NYSE:BHVN opened at $38.40 on Monday. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The firm ...